Suboptimal response or treatment failure to standard-dose imatinib are relevant problems in chronic-phase chronic myeloid leukemia patients. Insufficient adherence is one of the main causes of ...
A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP) No significant financial relationships to ...
Adherence to Initial Adjuvant Anastrozole Therapy Among Women With Early-Stage Breast Cancer Patients (N = 89) with varying solid tumors and liver function were stratified into four groups according ...
Ziftomenib plus Gleevec is being tested in a phase 1 trial for advanced GIST after Gleevec progression, showing promise in preclinical models. The combination targets GIST tumor weaknesses via a ...
Alexandria, VA--A new clinical study has shown that imatinib mesylate (Gleevec) has activity in AIDS-related Kaposi's sarcoma (KS). Imatinib inhibits important pathways that spur cancer growth, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results